RxDoctor Payments Data

Gerry Sertle

Family · Platteville, WINPI 1174780944

Payments from drug & device makers

$840in general payments, 2019–2025

Across 46 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$145
  • Johnson & Johnson$109
  • Neurocrine Biosciences, Inc.$104
  • AbbVie$72
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$68
  • Alkermes, Inc.$60
  • plus $282 from 10 others

What the payments were for

  • Food & beverage$79394%
  • Education$476%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$840 in reported general payments places this provider in the 80th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$15,513
Medicare patients
38
Services billed
194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate87$284,284
IngrezzaValbenazine Tosylate14$108,882
VraylarCariprazine Hcl50$77,209
LybalviOlanzapine/Samidorphan Malate29$51,709
RexultiBrexpiprazole35$51,618
AristadaAripiprazole Lauroxil11$35,005
FanaptIloperidone13$32,519
TrintellixVortioxetine Hydrobromide31$18,828
Paliperidone ErPaliperidone37$14,183
BelsomraSuvorexant20$9,214
Divalproex Sodium ErDivalproex Sodium57$6,830
Clozapine75$5,238
Aripiprazole48$3,391
Quetiapine Fumarate55$3,077
Oseltamivir Phosphate34$2,835

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$109$284,28487 claims
Neurocrine Biosciences, Inc.Ingrezza$104$108,88214 claims
Alkermes, Inc.Lybalvi, Aristada$60$86,71440 claims
AbbVieVraylar$72$77,20950 claims
Otsuka America Pharmaceutical, Inc.Rexulti$145$51,61835 claims
Vanda Pharmaceuticals Inc.Fanapt$32$32,51913 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$16$18,82831 claims
MerckBelsomra$18$9,21420 claims
Almatica Pharma LLCSertraline Hcl$17$65662 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,273 family providers in Wisconsin.

Other family in Platteville

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →